Clinical trial
A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced…
NCT00297089 · AbbVie (prior sponsor, Abbott), Industry · Completed
Key facts
| NCT number | NCT00297089 |
|---|---|
| Title | A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer |
| Official title | A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT 751 in Combination With Pemetrexed Versus Pemetrexed Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer |
| Lead sponsor | AbbVie (prior sponsor, Abbott), Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, NSCLC, Non-Small-Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | ABT-751, pemetrexed, placebo |
| Enrollment | 165 |
| Start date | Nov 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Feb 28, 2006 |
| Last update posted | Jan 31, 2013 |
| Countries | Czechia, Greece, Hungary, Netherlands, Slovakia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: